OPC 2025: Key Studies Shaping Lung Cancer Therapy From ASCO 2025
June 20th 2025At the 2025 Oncology Pharmacists Connect (OPC) meeting, Kevin Chen, PharmD, MS, BCOP, CPP, reviewed several key studies from the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting significant advancements in the treatment of small cell and non–small cell lung cancer.
OPC 2025: Early and Metastatic GI Cancers See Practice-Changing Trial Results
June 20th 2025At the 2025 Oncology Pharmacists Connect (OPC) meeting, Courtney Cavalieri, PharmD, BCOP, presented clinical trial findings in gastrointestinal (GI) cancers—including colon, gastric, pancreatic, and metastatic colorectal cancer—that highlight the expanding role of immunotherapy and targeted treatments.
OPC 2025: Advancing Precision Oncology Through Pharmacy-Led Innovation
June 19th 2025At the 2025 Oncology Pharmacists Connect (OPC) meeting, Mya Tran, PharmD, BCOP, highlights the clinical promise, operational challenges, and evolving role of pharmacists in implementing precision medicine and genomics-driven cancer care.
This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.
Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, Highlights Key Reasons to Attend OPC 2025
June 16th 2025Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, co-chair of the 2025 Oncology Pharmacists Connect (OPC) meeting, discusses what makes the event unique, highlights key sessions, and shares her excitement for the educational and networking opportunities.
You Shall Not Pass: Pharmacist Review of Drug-Herb Interactions in Cancer Treatment
This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.
BENEFIT Trial Results Show Quadruplet Regimen for NDMM TI May Require Weighing Efficacy vs Safety
June 21st 2024The quadruplet regimen added bortezomib to the current standard of care, which is a triplet regimen of isatuximab, lenalidomide, and dexamethasone for patients with transplant-ineligible, newly diagnosed multiple myeloma (NDMM TI).
Navigating the Complex Landscape of Cell and Gene Therapy: Challenges and Solutions
June 21st 2024There are numerous challenges with cell and gene therapies in oncology, such as accessibility, cost, and prior authorizations, as well as the need for improved education and training within the oncology community.